This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Investor Uprising Publishes Free Biotech Investment Report

Stocks in this article: FBIOXIBBPRHSXSHSAX

NEW YORK, June 1, 2011 /PRNewswire/ -- Investor Uprising ( www.investoruprising.com) has released "A Guide to Biotech Investing," a four-page, definitive guide to the best biotech Exchange Traded Funds (ETFs) and mutual funds, which is available free to registered users of the Website.

(Logo:   http://photos.prnewswire.com/prnh/20110411/NY80781LOGO-a )

"A Guide to Biotech Investing" analyzes the ongoing biotech bull market, identifying the leading biotech mutual funds and ETFs. It explains how individual investors can gain exposure to the biotech market to diversify their portfolios, as well as how to go about looking at a variety of biotech funds and ETFs.

"Biotech has been roaring forward, and not a lot of investors are aware of how to gain exposure to the market," says R. Scott Raynovich, editor-in-chief, Investor Uprising. "Biotech ETFs are a good play in an appealing investment sector with relatively low correlation to macro-economic problems."

Some biotech funds identified in the report are up more than 100% over the last five years, with less volatility than the Nasdaq Index. This report tells you why, and how to tell the funds apart. The report explains the components of the various biotech ETFs and which should be sought for either large-cap or mid-cap investments. The report compares the leading biotech funds and ETFs with leading technology ETFs.

The mutual funds and ETFs tracked by the report include the T. Rowe Price Health Sciences Fund (PRHSX), Fidelity Select Biotechnology fund (FBIOX), BlackRock Health Sciences Ops Inv A (SHSAX), Vanguard Healthcare ETF (VHT), First Trust NYSE Arca Biotech Index (NYSE: FBT), iShares Nasdaq Biotechnology Index (Nasdaq: IBB), and the SPDR S&P Biotech ETF (NYSE: XBI).

The report is the second in a series of free ground-breaking reports published on Investor Uprising and available to registered readers for free. Readers can register for the site here.

About Investor Uprising

Investor Uprising is the individual investor's no-nonsense community for accessing business trends and investment strategies. Combining expert market commentary, fundamental analysis and on-the-ground reporting, Investor Uprising helps the reader find the best investment opportunities in global markets. Sponsored by PR Newswire and operated by UBM plc, Investor Uprising's community of contributors will reach millions of potential business readers around the world.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs